Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
Tevogen Bio (Nasdaq: TVGN) CEO Ryan Saadi reaffirmed his commitment to preserving shareholder equity while discussing the company's financing strategy. The clinical-stage specialty immunotherapy biotech company emphasizes three key aspects of its approach:
1. Strong Asset Base: The company claims billions in asset value, though not reflected on the balance sheet due to US GAAP limitations on internally developed intangible assets.
2. Operational Efficiency: Reports approximately 600% higher market cap per employee compared to industry standards, according to NYU Stern School of Business.
3. Alternative Financing: Plans to secure funds through non-equity means before revenue generation begins.
The company maintains its focus on making advanced immunotherapies accessible and affordable, while offering share ownership to employees as part of its compensation strategy.
Tevogen Bio (Nasdaq: TVGN) Il CEO Ryan Saadi ha ribadito il suo impegno a preservare l'equità degli azionisti durante la discussione sulla strategia di finanziamento dell'azienda. L'azienda biotech specializzata in immunoterapia in fase clinica pone l'accento su tre aspetti chiave del suo approccio:
1. Solida Base di Attivi: L'azienda dichiara miliardi di valore attivo, sebbene non riflessi nel bilancio a causa delle limitazioni dei principi contabili statunitensi (US GAAP) sugli attivi immateriali sviluppati internamente.
2. Efficienza Operativa: Riporta un valore di mercato per dipendente circa 600% superiore rispetto agli standard del settore, secondo la NYU Stern School of Business.
3. Finanziamento Alternativo: Piani per garantire fondi attraverso mezzi non azionari prima dell'inizio della generazione di entrate.
L'azienda mantiene il suo focus nel rendere le immunoterapie avanzate accessibili e convenienti, offrendo al contempo la possibilità di possedere azioni ai dipendenti come parte della sua strategia di compensazione.
Tevogen Bio (Nasdaq: TVGN) El CEO Ryan Saadi reafirmó su compromiso de preservar el capital de los accionistas mientras discutía la estrategia de financiamiento de la empresa. La compañía biotecnológica especializada en inmunoterapia en etapa clínica enfatiza tres aspectos clave de su enfoque:
1. Fuerte Base de Activos: La empresa afirma tener miles de millones en valor de activos, aunque no se refleja en el balance debido a las limitaciones de US GAAP sobre los activos intangibles desarrollados internamente.
2. Eficiencia Operativa: Informa un valor de mercado por empleado aproximadamente 600% superior al estándar de la industria, según la NYU Stern School of Business.
3. Financiamiento Alternativo: Planea asegurar fondos a través de medios no accionariales antes de que comience la generación de ingresos.
La empresa mantiene su enfoque en hacer que las inmunoterapias avanzadas sean accesibles y asequibles, mientras ofrece la propiedad de acciones a los empleados como parte de su estrategia de compensación.
Tevogen Bio (Nasdaq: TVGN) CEO 라이언 사디는 회사의 자금 조달 전략에 대해 논의하면서 주주 가치를 보호하겠다는 의지를 재확인했습니다. 임상 단계의 전문 면역 요법 생명공학 회사는 접근 방식의 세 가지 주요 측면을 강조합니다:
1. 강력한 자산 기반: 회사는 수십억 달러의 자산 가치를 주장하지만, 내부에서 개발된 무형 자산에 대한 미국 GAAP의 제한으로 인해 재무제표에 반영되지 않습니다.
2. 운영 효율성: NYU 스턴 경영대학원에 따르면 업계 표준에 비해 직원당 시장 가치가 약 600% 더 높다고 보고합니다.
3. 대체 자금 조달: 수익 창출이 시작되기 전에 비주식 수단을 통해 자금을 확보할 계획입니다.
회사는 고급 면역 요법을 접근 가능하고 저렴하게 만드는 데 주력하며, 보상 전략의 일환으로 직원들에게 주식 소유권을 제공합니다.
Tevogen Bio (Nasdaq: TVGN) Le PDG Ryan Saadi a réaffirmé son engagement à préserver l'équité des actionnaires tout en discutant de la stratégie de financement de l'entreprise. La société biopharmaceutique spécialisée dans l'immunothérapie en phase clinique met l'accent sur trois aspects clés de son approche :
1. Solide Base d'Actifs : L'entreprise affirme disposer de milliards de valeur d'actifs, bien que cela ne soit pas reflété dans le bilan en raison des limitations des US GAAP sur les actifs incorporels développés en interne.
2. Efficacité Opérationnelle : Elle rapporte un capitalisation boursière par employé environ 600 % supérieure aux standards du secteur, selon la NYU Stern School of Business.
3. Financement Alternatif : Prévoit de sécuriser des fonds par des moyens non-actions avant le début de la génération de revenus.
L'entreprise reste concentrée sur la rendre les immunothérapies avancées accessibles et abordables, tout en offrant la possibilité de posséder des actions aux employés dans le cadre de sa stratégie de rémunération.
Tevogen Bio (Nasdaq: TVGN) CEO Ryan Saadi bekräftigte sein Engagement, das Eigenkapital der Aktionäre zu bewahren, während er die Finanzierungsstrategie des Unternehmens erörterte. Das biopharmazeutische Unternehmen, das sich auf klinische Immuntherapien spezialisiert hat, betont drei zentrale Aspekte seines Ansatzes:
1. Starke Vermögensbasis: Das Unternehmen gibt an, Milliarden an Vermögenswerten zu besitzen, die jedoch aufgrund der US-GAAP-Beschränkungen für intern entwickelte immaterielle Vermögenswerte nicht in der Bilanz ausgewiesen werden.
2. Betriebliche Effizienz: Berichtet von einem etwa 600% höheren Marktwert pro Mitarbeiter im Vergleich zu den Branchenstandards, laut NYU Stern School of Business.
3. Alternative Finanzierung: Plant, Mittel durch nicht-aktienbasierte Mittel zu sichern, bevor die Umsatzgenerierung beginnt.
Das Unternehmen konzentriert sich weiterhin darauf, fortschrittliche Immuntherapien zugänglich und erschwinglich zu machen, während es den Mitarbeitern im Rahmen seiner Vergütungsstrategie Aktienbesitz anbietet.
- Claims billions in asset value
- 600% higher market cap per employee versus industry average
- Strategy to avoid equity dilution for funding needs
- No current revenue generation
- Asset value not recognized on balance sheet due to GAAP restrictions
WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, reaffirms his commitment to preserving equity for shareholders. Amid ongoing discussions about financing approaches in the biotech sector, Dr. Saadi emphasizes his distinct strategy, which prioritizes efficiency, asset ownership, and a path to revenue.
“I’m not opposed to the concept of equity financing, I believe that preserving equity is fundamental to preserving a Founder’s vision,” said Ryan Saadi, Founder and CEO of Tevogen Bio. “From a practical standpoint, it’s simply not relevant to us when you consider the following:
- Strong Asset Base: Tevogen Bio believes its assets are valued in the billions. This value is not reflected on Tevogen’s balance sheet as internally developed intangible assets are generally not permitted to be capitalized as per US GAAP.
- Operational Efficiency: Tevogen Bio’s market cap per employee is approximately
600% higher than the industry according to Mr. Damodaran at the Stern School of Business at NYU. - Self-Sustaining Financing Strategy: While Tevogen may secure funds between now and when it starts generating revenue, it has multiple avenues to do so without selling equity.
Regarding the company:
- Tevogen’s true value will become more widely recognized as awareness grows.
- The best way to gain TVGN shares is through employment, as every employee is also a shareholder.
- Tevogen’s business model challenges traditional biotech financing norms to ensure long-term sustainability.
- The company remains committed to making advanced immunotherapies accessible and affordable.
About Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer; Tevogen’s plans to expand its efforts in artificial intelligence; Tevogen’s ability to develop additional product candidates; Tevogen’s use of funds from the grant; and the potential receipt of additional future grants. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What is Tevogen Bio's (TVGN) strategy for preserving shareholder equity?
How does Tevogen Bio's (TVGN) market cap per employee compare to industry standards?
What is the estimated value of Tevogen Bio's (TVGN) assets in 2025?
How does Tevogen Bio (TVGN) plan to handle financing before revenue generation?
